Baricitinib efficacy has been evaluated in a phase 2 trial [1] that showed an improvement on arthritis and muscu- loskeletal symptoms in SLE patients.
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus
Fornaro, Marco;Coladonato, Laura;Venerito, Vincenzo;Iannone, Florenzo
2019-01-01
Abstract
Baricitinib efficacy has been evaluated in a phase 2 trial [1] that showed an improvement on arthritis and muscu- loskeletal symptoms in SLE patients.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.